Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

European Journal of Immunology

Volumn 38, Issue 3, 2008, Pages 877-887

  Spohn, Gunther ^a   Keller, Iris ^a   Beck, Markus ^a   Grest, Paula ^b   Jennings, Gary T ^a   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Autoantibodies; Cytokines; Rheumatoid arthritis; Vaccination

Indexed keywords

COLLAGEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; AMINO ACID; AUTOANTIBODY; COLLAGEN TYPE 2; DEOXYPYRIDINOLINE; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SUBUNIT VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIOPHAGE; BAGG ALBINO MOUSE; BONE DEFECT; CARTILAGE DEGENERATION; CONTROLLED STUDY; CROSS LINKING; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VIRUS PARTICLE; ANIMAL; ANTIBODY PRODUCTION; ARTHRITIS; AUTOIMMUNE DISEASE; BLOOD; CHEMICALLY INDUCED DISORDER; COLIPHAGE; CROSS REACTION; DBA MOUSE; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METHODOLOGY; SERODIAGNOSIS; SYNTHESIS; VACCINATION;

ALLOLEVIVIRUS; AMINO ACIDS; ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COLLAGEN TYPE II; CROSS REACTIONS; FEMALE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-1 TYPE I; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SUBUNIT;

EID: 43649107676     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737989     Document Type: Article

References (43)

1. Pincus, T., Long-term outcomes in rheumatoid arthritis. Br. J. Rheumatol. 1995. 34 Suppl 2: 59-73.
2. Choy, E. H. and Panayi, G. S., Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001. 344: 907-916.
3. Dayer, J. M., The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003. 42 Suppl 2: Ii3-ii10.
4. Dinarello, C. A., Interleukin-1. Cytokine Growth Factor Rev. 1997. 8: 253-265.
5. Dinarello, C. A., Biologic basis for interleukin-1 in disease. Blood 1996. 87: 2095-2147.
6. Arend, W. P., The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002. 13: 323-340.
7. Firestein, G. S., Boyle, D. L., Yu, C., Paine, M. M., Whisenand, T. D., Zvaifler, N. J. and Arend, W. P., Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 1994. 37: 644-652.
8. Chomarat, P., Vannier, E., Dechanet, J., Rissoan, M. C., Banchereau, J., Dinarello, C. A. and Miossec, P., Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J. Immunol. 1995. 154: 1432-1439.
9. Svenson, M., Hansen, M. B., Thomsen, A. R., Diamant, M., Nansen, A., Rieneck, K., Otterness, I. G. et al., Cytokine vaccination: Neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. J. Immunol. Methods 2000. 236: 1-8.
10. Bertin-Maghit, S. M., Capini, C. J., Bessis, N., Chomilier, J., Muller, S., Abbas, A., Autin, L. et al., Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 2005. 23: 4228-4235.
11. Bachmann, M. F., Rohrer, U. H., Kundig, T. M., Burki, K., Hengartner, H. and Zinkernagel, R. M., The influence of antigen organization on B cell responsiveness. Science 1993. 262: 1448-1451.
12. Spohn, G., Schwarz, K., Maurer, P., Illges, H., Rajasekaran, N., Choi, Y., Jennings, G. T. et al., Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol. 2005. 175: 6211-6218.
13. Rohn, T. A., Jennings, G. T., Hernandez, M., Grest, P., Beck, M., Zou, Y., Kopf, M. et al., Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 2006. 36: 2857-2867.
14. Ambuhl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R., Nief, V. et al., A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity. J. Hypertens. 2007. 25: 63-72.
15. Spohn, G., Guler, R., Johansen, P., Keller, I., Jacobs, M., Beck, M., Rohner, F. et al., A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 2007. 178: 7450-7457.
16. Inoue, K., Masuko-Hongo, K., Okamoto, M. and Nishioka, K., Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice. Clin. Exp. Rheumatol. 2003. 21: 33-39.
17. Nandakumar, K. S. and Holmdahl, R., Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J. Immunol. Methods 2005. 304: 126-136.
18. Nandakumar, K. S., Backlund, J., Vestberg, M. and Holmdahl, R., Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res. Ther. 2004. 6: R544-R550.
19. Nandakumar, K. S., Svensson, L. and Holmdahl, R., Collagen type II-specific monoclonal antibody-induced arthritis in mice: Description of the disease and the influence of age, sex, and genes. Am. J. Pathol. 2003. 163: 1827-1837.
20. Abramson, S. B. and Amin, A., Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002. 41: 972-980.
21. Granowitz, E. V., Porat, R., Mier, J. W., Pribble, J. P., Stiles, D. M., Bloedow, D. C., Catalano, M. A. et al., Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992. 4: 353-360.
22. Graudal, N. A., Svenson, M., Tarp, U., Garred, P., Jurik, A. G. and Bendtzen, K., Autoantibodies against interleukin 1alpha in rheumatoid arthritis: Association with long term radiographic outcome. Ann. Rheum. Dis. 2002. 61: 598-602.
23. Svenson, M., Poulsen, L. K., Fomsgaard, A. and Bendtzen, K., IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand. J. Immunol. 1989. 29: 489-492.
24. Kagari, T., Doi, H. and Shimozato, T., The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 2002. 169: 1459-1466.
25. Nandakumar, K. S. and Holmdahl, R., Arthritis induced with cartilage-specific antibodiesis IL-4-dependent. Eur. J. Immunol. 2006. 36: 1608-1618.
26. Ji, H., Pettit, A., Ohmura, K., Ortiz-Lopez, A., Duchatelle, V., Degott, C., Gravallese, E. et al., Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J. Exp. Med. 2002. 196: 77-85.
27. Ohmura, K., Johnsen, A., Ortiz-Lopez, A., Desany, P., Roy, M., Besse, W., Rogus, J. et al., Variation in IL-1beta gene expression is a major determinant of genetic differences in arthritis aggressivity in mice. Proc. Natl. Acad. Sci. USA 2005. 102: 12489-12494.
28. Banda, N. K., Thurman, J. M., Kraus, D., Wood, A., Carroll, M. C., Arend, W. P. and Holers, V. M., Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 2006. 177: 1904-1912.
29. Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M., Boackle, S. A., Takahashi, K. et al., Arthritis critically dependent on innate immune system players. Immunity 2002. 16: 157-168.
30. Wallis, R. S., Broder, M., Wong, J. and Beenhouwer, D., Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin. Infect. Dis. 2004. 39: 1254-1255.
31. Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E. and Beenhouwer, D. O., Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 2004. 38: 1261-1265.
32. Slifman, N. R., Gershon, S. K., Lee, J. H., Edwards, E. T. and Braun, M. M., Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003. 48: 319-324.
33. Lee, J. H., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P. et al., Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002. 46: 2565-2570.
34. Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G. R., Tesser, J., Modafferi, D. et al., Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003. 48: 927-934.
35. Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G. R., Bennett, R., Modafferi, D. et al., Safety of extended treatment with Anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006. 65: 1006-1012.
36. Juffermans, N. P., Florquin, S., Camoglio, L., Verbon, A., Kolk, A. H., Speelman, P., van Deventer, S. J. et al., Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 2000. 182: 902-908.
37. Yamada, H., Mizumo, S., Horai, R., Iwakura, Y. and Sugawara, I., Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab. Invest. 2000. 80: 759-767.
38. Denis, M. and Ghadirian, E., Interleukin-1 is involved in mouse resistance to Mycobacterium avium. Infect. Immun. 1994. 62: 457-461.
39. Irikura, V. M., Hirsch, E. and Hirsh, D., Effects of interleukin-1 receptor antagonist overexpression on infection by Listeria monocytogenes. Infect. Immun. 1999. 67: 1901-1909.
40. Irikura, V. M., Lagraoui, M. and Hirsh, D., The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor. J. Immunol. 2002. 169: 393-398.
41. Hirsch, E., Irikura, V. M., Paul, S. M. and Hirsh, D., Functions of interleukin 1 receptor antagonist in gene knockout and overproducingmice. Proc. Natl. Acad. Sci. USA 1996. 93: 11008-11013.
42. Labow,M., Shuster, D., Zetterstrom, M., Nunes, P., Terry, R., Cullinan, E. B., Bartfai, T. et al., Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J. Immunol. 1997. 159: 2452-2461.
43. Jegerlehner, A., Storni, T., Lipowsky, G., Schmid, M., Pumpens, P. and Bachmann, M. F., Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 2002. 32: 3305-3314.